World Health Organization– tag –
-
Dexcom’s Investment Outlook Brightens as G7 CGM Gains Expanded Reimbursement for Type 2 Non-Insulin Diabetes Patients
Seeking Alpha USA Overview Dexcom's investment thesis has significantly improved following expanded insurance reimbursement for its G7 continuous glucose monitoring (CGM) systems, now covering a large population of type 2 non-insulin dia... -
AquaFluoSense Unveils Novel Quantum Dot Sensor for Water-Based Lead and Arsenic Detection at Nanomolar Limits: 1.2 nM Lead, 0.45 nM Arsenic Achieved
AZoNano International Overview AquaFluoSense has announced a portable nano-optical biosensor combining metal-specific aptamers, fluorescent quantum dots, and portable electronics to detect trace lead and arsenic in water. The system achi... -
Senseonics Eversense 365 Receives FDA Approval as World’s First Year-Long Wearable CGM, Expanded Medicare Coverage to Reshape Market
Constancy Researchers America Overview Senseonics' Eversense 365 has secured FDA approval, becoming the world's first commercially available year-long implantable continuous glucose monitor (CGM). This innovation fundamentally improves p... -
Dexcom Stelo Wins FDA Approval as First Prescription-Free OTC Continuous Glucose Monitor for Non-Insulin Users
Dexcom (via Facebook) USA Overview Dexcom's Stelo glucose biosensor system has received FDA approval as the first over-the-counter (OTC) continuous glucose monitor (CGM) for adults aged 18 and older who do not use insulin. This landmark ... -
Handheld RT-LAMP Assays Multiplex Detection of Chikungunya, Dengue, Mayaro, and Zika Viruses: Revolutionizing Diagnostics in Endemic Regions with POCT
Analytical Chemistry (ACS Publications) USA Overview This study demonstrated the robust performance of multiplex RT-LAMP assays in handheld devices for in-situ detection of Chikungunya, Dengue, Mayaro, and Zika viruses. The platform was ... -
MIT’s Non-Invasive Raman-Based CGM Achieves Accuracy Comparable to Commercial Devices, Signaling Next-Generation Glucose Monitoring Potential
Morld USA Overview MIT researchers have developed a novel Raman-based non-invasive continuous glucose monitoring (CGM) device that reads glucose through the skin without needles. Initial tests demonstrate accuracy comparable to existing ... -
FDA Clears Dexcom’s Stelo Glucose Biosensor System as First OTC Continuous Glucose Monitor for Non-Insulin-Using Children Ages 2+
Weence.com USA Overview On June 12, 2026, the FDA approved Dexcom's Stelo Glucose Biosensor System as the first over-the-counter (OTC) continuous glucose monitor (CGM) for children aged 2 and older who do not use insulin. This system, wh... -
Labman Develops Next-Gen POCT HPV Screening Device under EU ELEVATE Project: Rapid Detection of 14 HPV Strains and Two Biomarkers
News-Medical.net UK Overview Labman has developed a next-generation point-of-care (POCT) HPV screening device as part of the EU-funded ELEVATE project. This compact, portable instrument utilizes microfluidic 'lab-on-a-chip' technology to... -
FDA Clears Dexcom’s Stelo OTC Continuous Glucose Monitor for Non-Insulin Users Aged Two and Up
Prime Therapeutics - Portal USA Overview The FDA has granted over-the-counter (OTC) marketing authorization for Dexcom's Stelo Glucose Biosensor System, expanding its use to non-insulin users aged two and older. This marks the first OTC ... -
RT-CGM Reduces Inpatient and Emergency Department Encounters, Cutting Healthcare Costs for Non-Insulin-Treated Type 2 Diabetes Patients
PubMed USA Overview A retrospective study using US administrative claims data reveals that real-time continuous glucose monitoring (RT-CGM) significantly reduces healthcare resource utilization and associated medical costs among non-insu...
